ReViral Ltd., a Stevenage, UK and Durham, NC-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), closed a US $44m Series C financing.
The round was led by CR-CP Life Science Fund with participation from Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors. In conjunction with the funding, Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joined the ReViral Board of Directors.
The company intends to use the funds to conduct Phase 2 clinical development for sisunatovir, its wholly-owned fusion protein inhibitor, and to progress its N-protein replication inhibitor program into Phase 1.
Led by Alex Sapir, CEO, ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an adult stem-cell transplant patient population. In addition, the company has an N-protein replication inhibitor program in late preclinical development. Both programs were discovered in-house and the company has retained worldwide development and commercialization rights.